



Subject index

Volume 55 (2002)

Abacavir; Mycophenolate mofetil; Mycophenolic acid; Didanosine; Tenofovir; HIV-1; Antiretroviral resistance **55**, 41

Adefovir dipivoxil; Hepatitis B virus (HBV); Transgenic mouse; 3TC **55**, 27

Adenovirus; Adhesion; RGD; Integrin; Antiviral **55**, 169

Adenovirus; *Plantago major*; Caffeic acid; Chlorogenic acid; Herpes simplex virus; Phenolic compound **55**, 53

Adhesion; RGD; Integrin; Adenovirus; Antiviral **55**, 169

Adoptive cell therapy; HIV-1 infection; Poly-gene therapy; Antisense tRNA; VAI ribozyme **55**, 77

Animal model; Hepatitis B virus; Combination chemotherapy; Viral dynamics **55**, 381

Animal models; Oseltamivir phosphate; Influenza; Neuraminidase; Resistance **55**, 307

Anti-HSV-2 activity; *Terminalia arjuna* Linn.; Casuarinin; Hydrolyzable tannin; Combretaceae **55**, 447

Antiretroviral resistance; Mycophenolate mofetil; Mycophenolic acid; Abacavir; Didanosine; Tenofovir; HIV-1 **55**, 41

Antisense tRNA; HIV-1 infection; Poly-gene therapy; Adoptive cell therapy; VAI ribozyme **55**, 77

Antiviral activity; Ethylenediaminedisuccinic acid; Cytomegalovirus; Immunomodulatory activity **55**, 179

Antiviral activity; Milk protein; Electrostatic virus–cell interaction **55**, 341

Antiviral; Adhesion; RGD; Integrin; Adenovirus **55**, 169

Antiviral; Arenaviruses; Junin virus; Tacaribe virus; Disulfides; Virus inactivation **55**, 437

Antiviral; CD4-lymphocytes; HIV infection; Macrophages; Therapy; Drugs **55**, 209

Antiviral; Dispirotripiperazine; 5-Nitropyrimidine; Herpes simplex virus type 1 **55**, 117

Antiviral; Respiratory; Treatment **55**, 227

Antiviral therapy; Ebola virus; Filovirus; *S*-Adenosyl-L-homocysteine hydrolase; Interferon-alpha **55**, 151

antiviral therapy; Influenza; attachment inhibitor; sialylglycopolymer; mice **55**, 201

Antiviral; West Nile virus; Ribavirin; Flavivirus; 6-Azauridine **55**, 107

Arenaviruses; Junin virus; Tacaribe virus; Antiviral; Disulfides; Virus inactivation **55**, 437

attachment inhibitor; Influenza; sialylglycopolymer; antiviral therapy; mice **55**, 201

6-Azauridine; West Nile virus; Ribavirin; Antiviral; Flavivirus **55**, 107

Bovine viral diarrhea virus (BVDV); Interferon α -2b (IFN); *n*-Butyl deoxynojirimycin (*n*B-DNJ); Hepatitis C virus (HCV) **55**, 425

Caffeic acid; *Plantago major*; Chlorogenic acid; Herpes simplex virus; Adenovirus; Phenolic compound **55**, 53

Casuarinin; *Terminalia arjuna* Linn.; Anti-HSV-2 activity; Hydrolyzable tannin; Combretaceae **55**, 447

CD4-lymphocytes; HIV infection; Macrophages; Therapy; Drugs; Antiviral **55**, 209

Chimeric particles; HAV; Protein 2A; HIV gp41 **55**, 369

Chlorogenic acid; *Plantago major*; Caffeic acid; Herpes simplex virus; Adenovirus; Phenolic compound 55, 53

Cidofovir; Poxvirus; Smallpox; Variola; Vaccinia; Cowpox; Monkeypox; Molluscum contagiosum; Orf; Immunocompromised 55, 1

CMV423; Human cytomegalovirus; Immediate early antigens 55, 413

Combination chemotherapy; Hepatitis B virus; Animal model; Viral dynamics 55, 381

Combretaceae; *Terminalia arjuna* Linn.; Casuarinin; Anti-HSV-2 activity; Hydrolyzable tannin 55, 447

Cowpox; Cidofovir; Poxvirus; Smallpox; Variola; Vaccinia; Monkeypox; Molluscum contagiosum; Orf; Immunocompromised 55, 1

cp-52; RSV; Inhibition; Large unilamellar vesicles; F-protein; G-protein; Lipid composition; Dequenching assay 55, 189

Cytomegalovirus; Ethylenediaminedisuccinic acid; Antiviral activity; Immunomodulatory activity 55, 179

Cytomegalovirus protease; Herpesviruses; Drug target 55, 291

Dendrimer SPL-2999; Herpes simplex virus; Pre-clinical evaluation 55, 319

Dequenching assay; RSV; cp-52; Inhibition; Large unilamellar vesicles; F-protein; G-protein; Lipid composition 55, 189

Didanosine; Mycophenolate mofetil; Mycophenolic acid; Abacavir; Tenofovir; HIV-1; Antiretroviral resistance 55, 41

Dispirotripiperazine; 5-Nitropyrimidine; Herpes simplex virus type 1; Antiviral 55, 117

Disulfides; Arenaviruses; Junin virus; Tacaribe virus; Antiviral; Virus inactivation 55, 437

DNA dependent DNA polymerase; Hepatitis B virus polymerase; *Pichia methanolic*; RNA dependent DNA polymerase; RNase H 55, 279

Drugs; CD4-lymphocytes; HIV infection; Macrophages; Therapy; Antiviral 55, 209

Drug target; Cytomegalovirus protease; Herpesviruses 55, 291

Ebola virus; Filovirus; Antiviral therapy; S-Adenosyl-L-homocysteine hydrolase; Interferon-alpha 55, 151

Electrostatic virus-cell interaction; Milk protein; Antiviral activity 55, 341

Ethylenediaminedisuccinic acid; Cytomegalovirus; Antiviral activity; Immunomodulatory activity 55, 179

Filovirus; Ebola virus; Antiviral therapy; S-Adenosyl-L-homocysteine hydrolase; Interferon-alpha 55, 151

Flaviviridae; Hepatitis C virus; Nucleoside triphosphatase helicase; Target for antiviral therapy 55, 397

Flavivirus; West Nile virus; Ribavirin; Antiviral; 6-Azauridine 55, 107

F-protein; RSV; cp-52; Inhibition; Large unilamellar vesicles; G-protein; Lipid composition; Dequenching assay 55, 189

Ganciclovir; Herpes simplex virus; Herpes simplex thymidine kinase; N-Methanocarbothymidine; Phosphorylation; Plaque forming unit 55, 63

Gene cleavage; Transcription; Pathogenesis 55, 129

G-protein; RSV; cp-52; Inhibition; Large unilamellar vesicles; F-protein; Lipid composition; Dequenching assay 55, 189

HAV; Protein 2A; HIV gp41; Chimeric particles 55, 369

Hck; HIV; Nef; SH3; Mammalian two-hybrid system 55, 161

Hepatitis B virus; Combination chemotherapy; Animal model; Viral dynamics 55, 381

Hepatitis B virus (HBV); Adefovir dipivoxil; Transgenic mouse; 3TC 55, 27

Hepatitis B virus polymerase; *Pichia methanolic*; DNA dependent DNA polymerase; RNA dependent DNA polymerase; RNase H 55, 279

Hepatitis C virus (HCV); Interferon α -2b (IFN); n-Butyl deoxynojirimycin (nB-DNJ); Bovine viral diarrhea virus (BVDV) 55, 425

Hepatitis C virus; Nucleoside triphosphatase helicase; Flaviviridae; Target for antiviral therapy 55, 397

Herpes simplex thymidine kinase; Herpes simplex virus; N-Methanocarbothymidine; Ganciclovir; Phosphorylation; Plaque forming unit 55, 63

Herpes simplex virus; Dendrimer SPL-2999; Pre-clinical evaluation 55, 319

Herpes simplex virus; Herpes simplex thymidine kinase; N-Methanocarbothymidine; Ganciclovir; Phosphorylation; Plaque forming unit 55, 63

Herpes simplex virus; *Plantago major*; Caffeic acid; Chlorogenic acid; Adenovirus; Phenolic compound 55, 53

- Herpes simplex virus type 1**; Dispirotripiperazine; 5-Nitropyrimidine; Antiviral **55**, 117
- Herpesviruses**; Cytomegalovirus protease; Drug target **55**, 291
- HIV/AIDS**; Prognostic indicators; Treatment; Treatment guidelines **55**, 15
- HIV gp41**; HAV; Protein 2A; Chimeric particles **55**, 369
- HIV infection**; CD4-lymphocytes; Macrophages; Therapy; Drugs; Antiviral **55**, 209
- HIV-1 infection**; Poly-gene therapy; Adoptive cell therapy; Antisense tRNA; VAI ribozyme **55**, 77
- HIV-1**; Inhibition; Purification; HPLC; HIV-1 integrase; Inhibitors **55**, 91
- HIV-1 integrase**; HIV-1; Inhibition; Purification; HPLC; Inhibitors **55**, 91
- HIV-1**; Mycophenolate mofetil; Mycophenolic acid; Abacavir; Didanosine; Tenofovir; Antiretroviral resistance **55**, 41
- HIV**; Nef; Hck; SH3; Mammalian two-hybrid system **55**, 161
- HPLC**; HIV-1; Inhibition; Purification; HIV-1 integrase; Inhibitors **55**, 91
- HPV**; Transcription; Promoter; IL-10; STAT3 **55**, 331
- Human cytomegalovirus**; CMV423; Immediate early antigens **55**, 413
- Hydrolyzable tannin**; *Terminalia arjuna* Linn.; Casuarinin; Anti-HSV-2 activity; Combretaceae **55**, 447
- IL-10**; HPV; Transcription; Promoter; STAT3 **55**, 331
- Immediate early antigens**; Human cytomegalovirus; CMV423 **55**, 413
- Immunocompromised**; Cidofovir; Poxvirus; Smallpox; Variola; Vaccinia; Cowpox; Monkeypox; Molluscum contagiosum; Orf **55**, 1
- Immunomodulatory activity**; Ethylenediaminedisuccinic acid; Cytomegalovirus; Antiviral activity **55**, 179
- Influenza**; attachment inhibitor; sialylglycopolymer; antiviral therapy; mice **55**, 201
- Influenza**; Oseltamivir phosphate; Neuraminidase; Resistance; Animal models **55**, 307
- Inhibition**; HIV-1; Purification; HPLC; HIV-1 integrase; Inhibitors **55**, 91
- Inhibition**; RSV; *cp*-52; Large unilamellar vesicles; F-protein; G-protein; Lipid composition; Dequenching assay **55**, 189
- Inhibitors**; HIV-1; Inhibition; Purification; HPLC; HIV-1 integrase **55**, 91
- Integrin**; Adhesion; RGD; Adenovirus; Antiviral **55**, 169
- Interferon-alpha**; Ebola virus; Filovirus; Antiviral therapy; *S*-Adenosyl-L-homocysteine hydrolase **55**, 151
- Interferon α -2b (IFN)**; *n*-Butyl deoxynojirimycin (*n*B-DNJ); Hepatitis C virus (HCV); Bovine viral diarrhea virus (BVDV) **55**, 425
- Isothiazole derivatives**; Picornavirus; Measles **55**, 357
- Junin virus**; Arenaviruses; Tacaribe virus; Antiviral; Disulfides; Virus inactivation **55**, 437
- Lamivudine (3TC)**; Viral drug-resistance; Woodchuck hepatitis virus (WHV); Woodchuck (*Marmota monax*) **55**, 141
- Large unilamellar vesicles**; RSV; *cp*-52; Inhibition; F-protein; G-protein; Lipid composition; Dequenching assay **55**, 189
- Lipid composition**; RSV; *cp*-52; Inhibition; Large unilamellar vesicles; F-protein; G-protein; Dequenching assay **55**, 189
- Macrophages**; CD4-lymphocytes; HIV infection; Therapy; Drugs; Antiviral **55**, 209
- Mammalian two-hybrid system**; HIV; Nef; Hck; SH3 **55**, 161
- Measles**; Isothiazole derivatives; Picornavirus **55**, 357
- mice**; Influenza; attachment inhibitor; sialylglycopolymer; antiviral therapy **55**, 201
- Milk protein**; Antiviral activity; Electrostatic virus–cell interaction **55**, 341
- Molluscum contagiosum**; Cidofovir; Poxvirus; Smallpox; Variola; Vaccinia; Cowpox; Monkeypox; Orf; Immunocompromised **55**, 1

Monkeypox; Cidofovir; Poxvirus; Smallpox; Variola; Vaccinia; Cowpox; Molluscum contagiosum; Orf; Immunocompromised **55**, 1

Mycophenolate mofetil; Mycophenolic acid; Abacavir; Didanosine; Tenofovir; HIV-1; Antiretroviral resistance **55**, 41

Mycophenolic acid; Mycophenolate mofetil; Abacavir; Didanosine; Tenofovir; HIV-1; Antiretroviral resistance **55**, 41

***n*-Butyl deoxynojirimycin (*n*B-DNJ)**; Interferon α -2b (IFN); Hepatitis C virus (HCV); Bovine viral diarrhea virus (BVDV) **55**, 425

Nef; HIV; Hck; SH3; Mammalian two-hybrid system **55**, 161

Neuraminidase; Oseltamivir phosphate; Influenza; Resistance; Animal models **55**, 307

5-Nitropyrimidine; Dispirotriperazine; Herpes simplex virus type 1; Antiviral **55**, 117

***N*-Methanocarbothymidine**; Herpes simplex virus; Herpes simplex thymidine kinase; Ganciclovir; Phosphorylation; Plaque forming unit **55**, 63

Nucleoside triphosphatase helicase; Hepatitis C virus; Flaviviridae; Target for antiviral therapy **55**, 397

Orf; Cidofovir; Poxvirus; Smallpox; Variola; Vaccinia; Cowpox; Monkeypox; Molluscum contagiosum; Immunocompromised **55**, 1

Oseltamivir phosphate; Influenza; Neuraminidase; Resistance; Animal models **55**, 307

Pathogenesis; Transcription; Gene cleavage **55**, 129

Phenolic compound; *Plantago major*; Caffeic acid; Chlorogenic acid; Herpes simplex virus; Adenovirus **55**, 53

Phosphorylation; Herpes simplex virus; Herpes simplex thymidine kinase; *N*-Methanocarbothymidine; Ganciclovir; Plaque forming unit **55**, 63

Pichia methanolic; Hepatitis B virus polymerase; DNA dependent DNA polymerase; RNA dependent DNA polymerase; RNase H **55**, 279

Picornavirus; Isothiazole derivatives; Measles **55**, 357

Plantago major; Caffeic acid; Chlorogenic acid; Herpes simplex virus; Adenovirus; Phenolic compound **55**, 53

Plaque forming unit; Herpes simplex virus; Herpes simplex thymidine kinase; *N*-Methanocarbothymidine; Ganciclovir; Phosphorylation **55**, 63

Poly-gene therapy; HIV-1 infection; Adoptive cell therapy; Antisense tRNA; VAI ribozyme **55**, 77

Poxvirus; Cidofovir; Smallpox; Variola; Vaccinia; Cowpox; Monkeypox; Molluscum contagiosum; Orf; Immunocompromised **55**, 1

Pre-clinical evaluation; Dendrimer SPL-2999; Herpes simplex virus **55**, 319

Prognostic indicators; HIV/AIDS; Treatment; Treatment guidelines **55**, 15

Promoter; HPV; Transcription; IL-10; STAT3 **55**, 331

Protein 2A; HAV; HIV gp41; Chimeric particles **55**, 369

Purification; HIV-1; Inhibition; HPLC; HIV-1 integrase; Inhibitors **55**, 91

Resistance; Oseltamivir phosphate; Influenza; Neuraminidase; Animal models **55**, 307

Respiratory; Antiviral; Treatment **55**, 227

RGD; Adhesion; Integrin; Adenovirus; Antiviral **55**, 169

Ribavirin; West Nile virus; Antiviral; Flavivirus; 6-Azauridine **55**, 107

RNA dependent DNA polymerase; Hepatitis B virus polymerase; *Pichia methanolic*; DNA dependent DNA polymerase; RNase H **55**, 279

RNase H; Hepatitis B virus polymerase; *Pichia methanolic*; DNA dependent DNA polymerase; RNA dependent DNA polymerase **55**, 279

RSV; *cp*-52; Inhibition; Large unilamellar vesicles; F-protein; G-protein; Lipid composition; Dequenching assay **55**, 189

***S*-Adenosyl-L-homocysteine hydrolase**; Ebola virus; Filovirus; Antiviral therapy; Interferon-alpha **55**, 151

SH3; HIV; Nef; Hck; Mammalian two-hybrid system **55**, 161

sialylglycopolymer; Influenza; attachment inhibitor; antiviral therapy; mice **55**, 201

Smallpox; Cidofovir; Poxvirus; Variola; Vaccinia; Cowpox; Monkeypox; Molluscum contagiosum; Orf; Immunocompromised **55**, 1

STAT3; HPV; Transcription; Promoter; IL-10 **55**, 331

Tacaribe virus; Arenaviruses; Junin virus; Antiviral; Disulfides; Virus inactivation **55**, 437

Target for antiviral therapy; Hepatitis C virus; Nucleoside triphosphatase helicase; Flaviviridae **55**, 397

3TC; Adefovir dipivoxil; Hepatitis B virus (HBV); Transgenic mouse **55**, 27

Tenofovir; Mycophenolate mofetil; Mycophenolic acid; Abacavir; Didanosine; HIV-1; Antiretroviral resistance **55**, 41

***Terminalia arjuna* Linn.;** Casuarinin; Anti-HSV-2 activity; Hydrolyzable tannin; Combretaceae **55**, 447

Therapy; CD4-lymphocytes; HIV infection; Macrophages; Drugs; Antiviral **55**, 209

Transcription; Gene cleavage; Pathogenesis **55**, 129

Transcription; HPV; Promoter; IL-10; STAT3 **55**, 331

Transgenic mouse; Adefovir dipivoxil; Hepatitis B virus (HBV); 3TC **55**, 27

Treatment; Antiviral; Respiratory **55**, 227

Treatment guidelines; HIV/AIDS; Prognostic indicators; Treatment **55**, 15

Treatment; HIV/AIDS; Prognostic indicators; Treatment guidelines **55**, 15

Vaccinia; Cidofovir; Poxvirus; Smallpox; Variola; Cowpox; Monkeypox; Molluscum contagiosum; Orf; Immunocompromised **55**, 1

VAI ribozyme; HIV-1 infection; Poly-gene therapy; Adoptive cell therapy; Antisense tRNA **55**, 77

Variola; Cidofovir; Poxvirus; Smallpox; Vaccinia; Cowpox; Monkeypox; Molluscum contagiosum; Orf; Immunocompromised **55**, 1

Viral drug-resistance; Woodchuck hepatitis virus (WHV); Woodchuck (*Marmota monax*); Lamivudine (3TC) **55**, 141

Viral dynamics; Hepatitis B virus; Combination chemotherapy; Animal model **55**, 381

Virus inactivation; Arenaviruses; Junin virus; Tacaribe virus; Antiviral; Disulfides **55**, 437

West Nile virus; Ribavirin; Antiviral; Flavivirus; 6-Azauridine **55**, 107

Woodchuck hepatitis virus (WHV); Viral drug-resistance; Woodchuck (*Marmota monax*); Lamivudine (3TC) **55**, 141

Woodchuck (*Marmota monax*); Viral drug-resistance; Woodchuck hepatitis virus (WHV); Lamivudine (3TC) **55**, 141